Ferumoxytol

Ferumoxytol is a nanoparticle iron supplement used in the treatment of iron deficiency anemia in adults with chronic kidney disease. It is administered intravenously and is one of several iron-based products known as parenteral iron.

Overview[edit | edit source]

Ferumoxytol is a superparamagnetic iron oxide that is coated with a carbohydrate shell, which helps to isolate the bioactive iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. The iron is then released within the vesicles, transferred to the surface of the vesicle, and transported across the vesicle membrane where it can be stored as ferritin or released to transferrin for transport to other tissues.

Medical Uses[edit | edit source]

Ferumoxytol is used to treat iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is a common complication in patients with chronic kidney disease, especially those undergoing hemodialysis. Ferumoxytol is also used off-label for iron deficiency anemia in patients who cannot tolerate oral iron.

Side Effects[edit | edit source]

Common side effects of ferumoxytol include nausea, dizziness, and hypotension. Serious side effects may include allergic reactions, which can be life-threatening. Therefore, it is recommended that ferumoxytol be administered under the supervision of a healthcare professional.

Pharmacology[edit | edit source]

Ferumoxytol is a colloidal iron oxide product that is coated with a carbohydrate shell to help isolate the iron from plasma components until it enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow.

History[edit | edit source]

Ferumoxytol was approved by the Food and Drug Administration (FDA) in 2009 for the treatment of iron deficiency anemia in adults with chronic kidney disease.